ଉବ୍ରୋଗେପାଣ୍ଟ

ଉବ୍ରୋଗେପାଣ୍ଟ
Clinical data
Trade names	Ubrelvy
Synonyms	MK-1602
AHFS/Drugs.com	monograph
MedlinePlus	a620016
data	US DailyMed: Ubrogepant;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide;
Chemical and physical data
Formula	C29H26F3N5O3
Molar mass	୫୪୯.୫୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6;
	InChI InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1; Key:DDOOFTLHJSMHLN-ZQHRPCGSSA-N;

ଉବ୍ରୋଗେପାଣ୍ଟ (ଇଂରାଜୀ ଭାଷାରେ), ଏକ ବେପାର ନାମ ଉବ୍ରେଲଭି (Ubrelvy), ହେଉଛି ଅଧକପାଳି ରୋଗ ଆକ୍ରମଣର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୨] ଏଥିରେ ଏକ ଅରା (aura) ବା ଘବରେଇବା ଅନୁଭବ ଉପସ୍ଥିତ ଥିଲା କି ନାହିଁ ଜଣାଯାଇ ନାହିଁ ।^[୨] ଏହା ଅଧକପାଳି ପ୍ରତିରୋଧ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ନାହିଁ । ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ଥକାପଣ ଏବଂ ଶୁଖିଲା ପାଟି ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥା କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୪] ଶକ୍ତିଶାଳୀ ସିୱାଇପି୩ଏ୪ (CYP3A4) ଇନହିବିଟର ସହିତ ଏକତ୍ର ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୨] ଏହା ଏକ ଛୋଟ-ଅଣୁ- କାଲସିଟୋନିନ୍ ଜିନ୍ ସମ୍ବନ୍ଧୀୟ ପେପ୍ଟାଇଡ୍ ରିସେପ୍ଟର ଆଣ୍ଟାଗନିଷ୍ଟ । ^[୨]

୨୦୧୯ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଉବ୍ରୋଗେପାଣ୍ଟ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ୧୦୦ ମିଗ୍ରା ବିଶିଷ୍ଟ ବଟିକାର ମୂଲ୍ୟ ପ୍ରାୟ ୮୭ ଡଲାର ଥିଲା ।^[୬] ୨୦୨୧ ସୁଦ୍ଧା ଏହା ୟୁରୋପରେ ଅନୁମୋଦିତ ହୋଇନାହିଁ ^[୭]

ଆଧାର ସମ୍ପାଦନା

↑ "Ubrelvy- ubrogepant tablet". DailyMed. Archived from the original on 4 June 2021. Retrieved 4 June 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "Ubrogepant Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 12 August 2021.
↑ "FDA approves new treatment for adults with migraine" (Press release). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019.
↑ "Ubrogepant (Ubrelvy) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 March 2021. Retrieved 12 August 2021.
↑ Scott, LJ (February 2020). "Ubrogepant: First Approval". Drugs. 80 (3): 323–328. doi:10.1007/s40265-020-01264-5. PMID 32020557.
↑ "Ubrogepant Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 12 August 2021.
↑ "Ubrogepant". SPS - Specialist Pharmacy Service. Archived from the original on 27 August 2021. Retrieved 13 August 2021.

[Ubrelvy_FDA_label-1] "Ubrelvy- ubrogepant tablet". DailyMed. Archived from the original on 4 June 2021. Retrieved 4 June 2021.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "Ubrogepant Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 12 August 2021.

[FDA_PR-3] "FDA approves new treatment for adults with migraine" (Press release). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019.

[4] "Ubrogepant (Ubrelvy) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 March 2021. Retrieved 12 August 2021.

[Scott2020-5] Scott, LJ (February 2020). "Ubrogepant: First Approval". Drugs. 80 (3): 323–328. doi:10.1007/s40265-020-01264-5. PMID 32020557.

[GX2021-6] "Ubrogepant Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 12 August 2021.

[7] "Ubrogepant". SPS - Specialist Pharmacy Service. Archived from the original on 27 August 2021. Retrieved 13 August 2021.

[୨]

[୩]

[୧]

[୪]

[୫]

[୬]

[୭]